Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + lenalidomide + dexamethasone induction followed by lenalidomide maintenance in Waldenström's macroglobulinemia
KCT0003255Phase 2Completed
- Sponsor
- Celltrion
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, lenalidomide, dexamethasone, bortezomib in Waldenström macroglobulinemia (WM), sponsored by Celltrion. Started Mar 2019; status: completed.
02
Drugs
rituximablenalidomidedexamethasonebortezomib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on KCT0003255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003255.